Why royalties for Yuhan’s Leclaza were reduced $300mil
By Chon, Seung-Hyun | translator Alice Kang
24.09.23 05:03:09
가나다라
0
Terminates research for a 4th generation anticancer drug with Janssen…reducing the total amount of milestone payments payable
Signed a USD 1.255 billion deal in 2018...The next-generation therapy study FDA approval ended the next-generation study
Received USD 210 million in technology fees...may receive additional technology fees up to USD 740 million
The maximum contract amount for Leclaza, which was licensed out to Janssen by Yuhan Corp, has been reduced by USD 350 million. This reduction was due to the termination of research to develop Leclaza as a next-generation anti-cancer drug. Yuhan Corp received USD 210 million as upfront payment and development and approval milestones for the licensing agreement and is eligible to receive up to USD 740 million upon further development and sales.
▲Pic of Yuhan Corp headquarters
On the 20th, Yuhan Corp publicly announced that the maximum deal for Leclaza’s technology transfer agreement with Janssen Biotech has been reduced by USD 350 million (KRW 406.5 billion) from USD 1.255 billion to USD 950 million.The company explaine
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)